Please ensure Javascript is enabled for purposes of website accessibility

4 Headline Moving Health-Care Stocks

By Dave Williamson – Updated Apr 7, 2017 at 12:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In this video, health-care analysts David Williamson and Max Macaluso discuss four big headlines impacting some of the most popular stocks in the space. Watch and find out what it all means for investors.

The biotech space can make or destroy investors overnight, and Amarin, with its potential blockbuster drug, will be no different. The company has huge potential, but don't invest today before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here to keep reading. 

David Williamson owns shares of Amarin Corporation, but he holds no other position in any company mentioned. The Motley Fool owns shares of Dendreon. Motley Fool newsletter services recommend Vertex Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Stock Quote
Amarin
AMRN
$1.17 (%)
Vertex Pharmaceuticals Stock Quote
Vertex Pharmaceuticals
VRTX
$312.98 (-1.01%) $-3.18
Cantel Medical Stock Quote
Cantel Medical
CMD

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.